FTSE MIB
34.250,46 +310,71 (+0,92%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,19 +0,62 (+0,74%) Bitcoin EUR
59.663,60 +864,29 (+1,47%)
Ionis Pharmaceuticals, Inc. (IONS)
Dopo ore:
| Chiusura precedente | 42,45 |
| Aperto | 42,50 |
| Denaro | 41,79 x 300 |
| Lettera | 41,86 x 300 |
| Min-Max giorno | 41,58 - 42,72 |
| Intervallo di 52 settimane | 34,32 - 54,44 |
| Volume | |
| Media Volume | 1.077.988 |
| Capitalizzazione | 6,098B |
| Beta (5 anni mensile) | 0,40 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,56 |
| Prossima data utili | 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 55,95 |
GlobeNewswirePraxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insigh
GlobeNewswireNew Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community.
